158 related articles for article (PubMed ID: 23512167)
1. The in vivo pharmacodynamics of the novel opioid receptor antagonist, TD-1211, in models of opioid-induced gastrointestinal and CNS activity.
Armstrong SR; Campbell CB; Richardson CL; Vickery RG; Tsuruda PR; Long DD; Hegde SS; Beattie DT
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):471-8. PubMed ID: 23512167
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
Greenwood-Van Meerveld B; Gardner CJ; Little PJ; Hicks GA; Dehaven-Hudkins DL
Neurogastroenterol Motil; 2004 Oct; 16 Suppl 2():46-53. PubMed ID: 15357851
[TBL] [Abstract][Full Text] [Related]
3. The in vitro pharmacological profile of TD-1211, a neutral opioid receptor antagonist.
Tsuruda PR; Vickery RG; Long DD; Armstrong SR; Beattie DT
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jun; 386(6):479-91. PubMed ID: 23549670
[TBL] [Abstract][Full Text] [Related]
4. In vivo characterization of the opioid antagonist nalmefene in mice.
Osborn MD; Lowery JJ; Skorput AG; Giuvelis D; Bilsky EJ
Life Sci; 2010 Apr; 86(15-16):624-30. PubMed ID: 20159022
[TBL] [Abstract][Full Text] [Related]
5. The in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexone.
Beattie DT; Cheruvu M; Mai N; O'Keefe M; Johnson-Rabidoux S; Peterson C; Kaufman E; Vickery R
Naunyn Schmiedebergs Arch Pharmacol; 2007 May; 375(3):205-20. PubMed ID: 17340127
[TBL] [Abstract][Full Text] [Related]
6. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist.
Schmidt WK
Am J Surg; 2001 Nov; 182(5A Suppl):27S-38S. PubMed ID: 11755894
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists.
Russell J; Bass P; Goldberg LI; Schuster CR; Merz H
Eur J Pharmacol; 1982 Mar; 78(3):255-61. PubMed ID: 7200037
[TBL] [Abstract][Full Text] [Related]
8. Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain.
Webster L; Jansen JP; Peppin J; Lasko B; Irving G; Morlion B; Snidow J; Pierce A; Mortensen E; Kleoudis C; Carter E
Pain; 2008 Jul; 137(2):428-440. PubMed ID: 18164818
[TBL] [Abstract][Full Text] [Related]
9. The involvement of the mu-opioid receptor in gastrointestinal pathophysiology: therapeutic opportunities for antagonism at this receptor.
DeHaven-Hudkins DL; DeHaven RN; Little PJ; Techner LM
Pharmacol Ther; 2008 Jan; 117(1):162-87. PubMed ID: 18022696
[TBL] [Abstract][Full Text] [Related]
10. The selective mu opioid receptor antagonist, alvimopan, improves delayed GI transit of postoperative ileus in rats.
Fukuda H; Suenaga K; Tsuchida D; Mantyh CR; Pappas TN; Hicks GA; Dehaven-Hudkins DL; Takahashi T
Brain Res; 2006 Aug; 1102(1):63-70. PubMed ID: 16797494
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.
Divin MF; Holden Ko MC; Traynor JR
Eur J Pharmacol; 2008 Mar; 583(1):48-55. PubMed ID: 18275956
[TBL] [Abstract][Full Text] [Related]
12. Morphine withdrawal precipitated by specific mu, delta or kappa opioid receptor antagonists: a c-Fos protein study in the rat central nervous system.
Le Guen S; Gestreau C; Besson JM
Eur J Neurosci; 2003 Jun; 17(11):2425-37. PubMed ID: 12814374
[TBL] [Abstract][Full Text] [Related]
13. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.
Abul-Husn NS; Sutak M; Milne B; Jhamandas K
Br J Pharmacol; 2007 Jul; 151(6):877-87. PubMed ID: 17502848
[TBL] [Abstract][Full Text] [Related]
14. A review of the potential role of methylnaltrexone in opioid bowel dysfunction.
Foss JF
Am J Surg; 2001 Nov; 182(5A Suppl):19S-26S. PubMed ID: 11755893
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the peripheral and central effects of the opioid agonists loperamide and morphine in the formalin test in rats.
Shannon HE; Lutz EA
Neuropharmacology; 2002 Feb; 42(2):253-61. PubMed ID: 11804622
[TBL] [Abstract][Full Text] [Related]
16. Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid micro-agonists in an antinociception assay.
Sterious SN; Walker EA
J Pharmacol Exp Ther; 2003 Jan; 304(1):301-9. PubMed ID: 12490605
[TBL] [Abstract][Full Text] [Related]
17. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
[TBL] [Abstract][Full Text] [Related]
18. Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys.
Bowen CA; Fischer BD; Mello NK; Negus SS
J Pharmacol Exp Ther; 2002 Jul; 302(1):264-73. PubMed ID: 12065726
[TBL] [Abstract][Full Text] [Related]
19. Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ-opioid receptors in mice.
Matsumoto K; Umemoto H; Mori T; Akatsu R; Saito S; Tashima K; Shibasaki M; Kato S; Suzuki T; Horie S
Eur J Pharmacol; 2016 Jan; 771():220-8. PubMed ID: 26712376
[TBL] [Abstract][Full Text] [Related]
20. Acute delta- and kappa-opioid agonist pretreatment potentiates opioid antagonist-induced suppression of water consumption.
White DA; Ballard ME; Harmon AC; Holtzman SG
Brain Res Bull; 2008 Aug; 76(6):597-604. PubMed ID: 18598850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
